---
title: "Insilico Medicine, SK Biopharmaceuticals enter AI drug R&D collaboration worth up to USD 2.5 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290383515.md"
description: "Insilico Medicine and SK Biopharmaceuticals have entered a collaboration for AI-driven drug discovery targeting neuroimmune disorders. Insilico will utilize its Pharma.AI platform for candidate discovery, while SK Biopharmaceuticals leads late-stage development and commercialization. The deal has a total potential value of up to USD 2.5 billion, including milestones and royalties, with Insilico eligible for up to USD 18 million in upfront payments."
datetime: "2026-06-22T04:26:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290383515.md)
  - [en](https://longbridge.com/en/news/290383515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290383515.md)
---

# Insilico Medicine, SK Biopharmaceuticals enter AI drug R&D collaboration worth up to USD 2.5 billion

-   Insilico Medicine Cayman Topco entered an AI-driven drug discovery collaboration with SK Biopharmaceuticals focused on neuroimmune disorders in the central nervous system. \* Insilico will use its Pharma.AI platform to discover and optimize candidates; SK Biopharmaceuticals will lead late-stage development, clinical work, and commercialization. \* Insilico is eligible for up to USD 18 million in upfront and near-term milestones. \* Total potential value exceeds USD 2.5 billion, including development, regulatory, commercial milestones, and single-digit royalties on net sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260622-12209770), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)

## Related News & Research

- [11:39 ETInsilica CEO Co-Authors New Framework to Standardize High-Stakes AI in Toxicology](https://longbridge.com/en/news/288746451.md)
- [Insilico, US partner to build AI models predicting disease decades ahead](https://longbridge.com/en/news/287700035.md)
- [This AI stock recaptures key level, eyes entry as earnings accelerate](https://longbridge.com/en/news/290239182.md)
- [TrialAssure and Cancer Research UK Collaborate to Advance AI-Supported Regulatory Document Authoring](https://longbridge.com/en/news/290203206.md)
- [I built an AI tool that negotiated hotel prices for me. One hotel suspected it was AI, but it got me a better deal.](https://longbridge.com/en/news/290287200.md)